Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulinastatin for Cardiac Dysfunction in Cardiopulmonary Bypass
NCT05534802Completed
- Start
- Sep 2022
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of ulinastatin in Cardiac dysfunction and capillary leak syndrome (SCLS). Primary endpoints: Ejection Fraction at 7 days and Fractional Shortening at 7 days. Started Sep 2022; status: completed.
02
Drugs
ulinastatin
03
Conditions
Cardiac dysfunctioncapillary leak syndrome (SCLS)
Beyond the preview
Go deeper on NCT05534802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05534802.